MetaVia Inc. announced financial results for the year ended December 31, 2025, reporting net loss of $13.0 million or $7.35 per share, R&D expenses of $6.8 million, G&A expenses of $6.9 million, and cash of $10.3 million. The company highlighted positive Phase 1 data for DA-1726 showing 9.1% weight loss and upcoming Phase 1 Part 3 study initiation in April 2026.
Key takeaways
Net loss $13.0 million or $7.35 per basic and diluted share for year ended December 31, 2025 on 1,766,026 weighted average shares
R&D expenses $6.8 million for 2025 vs $21.6 million for 2024
G&A expenses $6.9 million for 2025 vs $7.3 million for 2024
Cash and cash equivalents $10.3 million as of December 31, 2025; expected to fund operations into Q4 2026 with January 2026 public offering proceeds of $9.3 million gross